Cost-Utility Analysis of Antihemophilic Factor Rfviii-Fs for Secondary Prophylaxis Vs on-Demand Therapy In Severe Haemophilia A In Italy.
Value in health : the journal of the…
View on PubMed
Abstract & Figures
Sorry, we couldn't extract an abstract for this paper.
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.
Sorry, we couldn't extract any citations for this paper.
Sorry, we couldn't extract any references for this paper.
Loading similar papers…
Slides referencing similar topics
Treatment For Life Prophylaxis in Haemophilia A is more cost-effective than on-demand therapy in a cost-utility model
Albert Farrugia + 6 • Oct 19, 2017
IPSG Survey: US Findings Prophylaxis regimens used in adults with severe Hemophilia A and no inhibitors
Barbara Konkle • Aug 27, 2017
An In-Depth Analysis of Data Aggregation Cost Factors in a Columnar In-Memory Database
Stephan Müller + 1 • Jul 06, 2015